European Medical Solutions (FRA:AS0) ROCE % : -10.17% (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is European Medical Solutions ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. European Medical Solutions's annualized ROCE % for the quarter that ended in Dec. 2023 was -10.17%.

European Medical Solutions ROCE % Historical Data

The historical data trend for European Medical Solutions's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

European Medical Solutions ROCE % Chart

European Medical Solutions Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-975.87

-0.53

-24.75

-1.18

European Medical Solutions Semi-Annual Data
	Dec13	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
ROCE %	Get a 7-Day Free Trial															-0.03	-34.94	-11.72	8.25	-10.17

European Medical Solutions ROCE % Calculation

European Medical Solutions's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-0.278	/	( ( (39.894 - 17.633)	+	(43.758 - 18.983) )	/ 2 )
	=	-0.278	/	( (22.261	+	24.775)	/ 2 )
	=	-0.278	/	23.518
	=	-1.18 %

European Medical Solutions's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	-2.398	/	( ( (42.535 - 20.161)	+	(43.758 - 18.983) )	/ 2 )
	=	-2.398	/	( ( 22.374	+	24.775 )	/ 2 )
	=	-2.398	/	23.5745
	=	-10.17 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2023) EBIT data.

European Medical Solutions (FRA:AS0) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

European Medical Solutions ROCE % Related Terms

Thank you for viewing the detailed overview of European Medical Solutions's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

European Medical Solutions (FRA:AS0) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » European Medical Solutions (FRA:AS0) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

ALIMG:Belgium

Address

7 Rue des Chasseurs Ardennais, Liege, BEL, 4031

Website

https://www.dms-imaging.com

DMS Imaging SA is a clinical-stage biopharmaceutical company. The company is engaged in the development and future commercialization of a range of breakthrough immunotherapy products for the treatment of allergies, based on its ASIT+ technology platform. Its lead product is gp-ASIT+, a phase III trial for the treatment of grass pollen rhinitis. Its pipeline products consist of hdm-ASIT+ for the treatment of house dust mite asthma; and pnt-ASIT+ for the treatment of peanut allergy.

European Medical Solutions (FRA:AS0) Headlines

No Headlines